Home / Platform
The Cytognosis Platform

A GPS for human health.

Every road trip needs three things: a map, a signal for where you are, and directions for where to go next. Cytognosis builds the same three things for your biology. Cytoverse draws the map. Cytoscope reads your position on it. Cytonome charts the route forward, years before symptoms would otherwise send you to a doctor.

Cytoverse draws the map, Cytoscope reads your position on it, and Cytonome charts the route forward, recalculating as your health changes.
This is an illustrative schematic, not a real map or measurement: a grid representing Cytoverse, a pulsing position marker representing Cytoscope, and a dashed route line representing Cytonome, all on the same shared map.
Reactive, today

“You have diabetes.”

Proactive, with Cytognosis

“Your metabolic coordinates are shifting. Adjust your circadian timing to restore your trajectory.”

The problem

The same label can hide different biology.

A cough can be a cold, the flu, or COVID-19: one symptom, three distinct causes, three distinct responses.
Text description: one symptom label at the left branches into distinct biotypes in the middle, each with its own underlying mechanism, each connecting to its own matched response on the right. This animation plays once and then relabels itself from the cough analogy to depression, using the same shapes for both. This is an illustrative schematic, not real patient data, and does not represent a diagnosis.

Two people can carry the same diagnosis and respond to completely different treatments, because the diagnosis describes a symptom, not a cause. Modern psychiatry has no routine way to measure the biology underneath a label, so care runs on trial and error instead of mechanism.

~1 in 3

patients respond to their first depression treatment, despite more than $22B in NIH depression research.

2–6 months

is how long each medication trial takes before anyone knows whether it worked.

21–33%

of patients need two to four trials before finding one that helps.

The fix, in one line

Biotyping resolves one label into the distinct, mechanism-linked patterns hiding inside it, so treatment can be matched to the biology in front of the clinician, not the average patient in the label.

These mechanisms are not neatly boxed by diagnosis either. The same underlying biological factors recur across labels, which is why a genuinely useful map has to work across diagnoses, not one disorder at a time. The reason this gap persists is not neglect: understanding an individual’s disease biology is not something a company can patent, so the step that would fix diagnosis is the step the market has the least incentive to build. That is the market failure Cytognosis exists to close as a nonprofit.

How it works

Three technologies, working as one loop.

The map

Cytoverse turns a diagnosis into a precise position on a map of human biology.

Two people who share a label but not a cause finally look different on the map.

How this changes care today
  • Today: clinicians treat people who share a diagnosis as if they share a cause. Cytognosis: Cytoverse gives each person their own Universal Health Coordinates, precise enough to catch subtle shifts and track them over time.
  • Today: diagnosis relies on symptom clusters, with little insight into the biology driving them. Cytognosis: Cytoverse combines detailed health profiles with the genetic and cellular drivers behind them.
A coordinate is a bundle of five things, not one number. Select a chip to isolate each part.
Text description: a single glowing point in a two-axis biological space, with a fading trail showing recent movement, a faint ghost marker at this person’s own baseline, and a dashed halo whose size reflects uncertainty. Illustrative example, not real patient data.
The sensor

Cytoscope watches dozens of molecular signals at once, continuously.

The way a continuous glucose monitor watches one, so a slow drift toward illness is visible long before symptoms are.

How Cytoscope decides where to look
  1. Start wide. A broad, low-detail scan establishes a person’s general position on the map.
  2. Zoom in on what matters. That scan, combined with personal information like genetics, points to the signals worth a closer look.
  3. Go all the way down, only there. Cytoscope zooms to single-cell detail only at those spots, not everywhere.
  4. Keep adjusting. As health shifts over months and years, Cytoscope follows the story wherever it moves.
The navigator

Cytonome turns those signals into a specific, personal next step.

Computed on a person’s own device, so their raw biology never has to leave their hands.

How this changes care today
  • Today: finding the right treatment often means trial and error, based on population averages. Cytognosis: Cytonome matches interventions to each person’s specific biotype.
  • Today: clinical decisions mostly wait until a problem crosses a diagnostic threshold. Cytognosis: Cytonome looks for change while it is still reversible, often years before a condition becomes permanent.
map sense navigate repeat
Why one scale is never enough

Biology hides at every scale. We look at all of them.

A genetic risk factor, a disrupted brain pathway, and a mood symptom can all trace back to the same underlying cause, but each one is invisible from a different angle. Cytognosis is built to bridge scales that are normally studied in isolation.

Biotypes across four scales: genomic, cellular, connectomic, and phenotypic Four horizontal bands, each showing a small representative pattern for genomic, cellular, connectomic, and phenotypic data, with connecting lines showing where the same disorder appears in more than one scale. Genomic SZ BD MDD 5 factors, ~12+ disorders Cellular SZ BD SZ + BD, 2-factor archetype (postmortem only) Connectomic MDD Depression, 4 connectivity subtypes (Drysdale et al. 2017) Phenotypic Symptom and behavior tracking, across disorders
Schizophrenia / Bipolar (shared cellular archetype) Depression

Cellular data is the scarce scale: it exists almost only in postmortem brain tissue, so today it is only generated for a handful of disorders. Genomic, connectomic, and phenotypic data are far more available. Rather than wait for cellular data that mostly does not exist yet, Cytognosis estimates the cellular picture from the other scales, and checks that estimate against real tissue as it becomes available. No single scale would let us do that; only having all of them lets one scale fill in for another. This is an illustrative schematic, not real patient data.

Breadth, honestly shown

Fourteen disorders, curated for their biology, not just their name.

Four circuits recur across several of these disorders. Six of the fourteen have no brain region named in our current research, and we show that honestly rather than filling in a guess.

A stylized brain map of four transdiagnostic circuits A simplified, illustrative brain outline with seven labeled points, dorsolateral prefrontal cortex, subgenual anterior cingulate, amygdala, ventromedial prefrontal cortex, nucleus accumbens, orbitofrontal cortex, and caudate, connected by four lines representing named transdiagnostic circuits. dlPFC sgACC Amygdala vmPFC NAc OFC Caudate
Hover or select a circuit, or click a disorder, to see its associated symptom domain.
Illustrative schematic, not an anatomical scan and not patient data. Circuit-to-domain pairings are literature-informed associations, not confirmed one-to-one causes.
Depression Substance use Psychosis / mania (cellular) Anxiety (+ dissociation) Repetitive thoughts & behaviors No adult domain / pediatric-only
Major depressive disorder1,600
Alcohol use disorder1,399
Schizophrenia~1,038
Opioid use disorder887
Bipolar disorder620–675
Nicotine use disorder639
Cannabis use disorder518
Generalized anxiety disorder510
PTSD285
ADHD249
Autism spectrum disorder~131
Anorexia nervosa84
OCD78
Tourette syndrome68

Bar length shows postmortem brain-tissue donor count (NIH NeuroBioBank), the most complete dataset we have across all fourteen. Circuit assignment is shown only where the source research names one.

See the full multiscale map on Psychoverse .

Continuous cross-scale monitoring

Watching biology move, years before behavior shows it.

A worked, illustrative example using depression. Monitoring starts wherever it is easiest to reach, an accessible marker like blood BDNF. As that marker moves in a positive direction, attention does not stop there: it adaptively shifts deeper, first to the brain circuit linked to depression, then, over a longer horizon, to the genomic pattern underneath both.

A diagnosis is a threshold event: before it, the system reports nothing unusual; after it, everything changes at once. A trajectory model tracks the same signal as motion instead, revealing a prevention window that a single snapshot cannot show.

A label is assigned at the threshold. Before it, the system reports nothing unusual; after it, everything changes at once.
Text description: toggle between a flat line that jumps abruptly at a vertical diagnosis threshold, and a smooth rising curve of the same underlying data with a shaded prevention window. This is an illustrative example, not real patient data.
Molecular, circuit, genomic, and behavioral biotype signals, tracked over twelve months for one illustrative depression example, with an adaptive focus marker
Baseline

All tracked biotypes near personal baseline. No action needed.

Monitoring focus: Molecular (BDNF/TrkB), the most accessible marker.

Text description: this diagram follows one illustrative, hypothetical example of depression-relevant biotypes across four lanes, Molecular (BDNF/TrkB), Circuit (connectivity subtype / dlPFC–sgACC), Genomic (background, slowest-moving), and Behavioral/symptom, over twelve months. A single glowing focus marker starts on the Molecular lane and hops deeper, to Circuit and then Genomic, only as each shallower marker trends positive, dramatizing how monitoring adaptively deepens rather than tracking every scale at full intensity all the time. This is an illustrative example, not real patient data, and does not represent a diagnosis or treatment.

The first application

Psychoverse is the platform, built for the brain.

Psychoverse is what Cytoverse becomes when it is pointed at neuropsychiatry: the same map, sensor, and navigator idea, built out across genomic, cellular, connectomic, and phenotypic data for mental health. Psychoverse works across four kinds of data, genetic risk, brain and cell biology, brain-circuit activity, and everyday symptoms and behavior, fusing whichever are available for a person and estimating the rest.

Genomic

Inherited risk factors shared across labels.

Cellular

Brain and cell biology, where tissue allows.

Connectomic

Brain-circuit activity and connectivity.

Phenotypic

Everyday symptoms and behavior over time.

Research program

Psychoverse

Open, non-diagnostic research infrastructure for studying continuous phenotype dimensions across genomic, circuit, physiological, and behavioral signals.

  • Longitudinal context over static labels
  • Mechanism-linked, auditable research
  • Clear uncertainty and no clinical claims
Explore Psychoverse
Personal companion

Yar

A local-first, voice-aware cognitive companion for neurodivergent adults: capture, thought organization, flexible planning, and gentle self-understanding.

  • Private by default and consent-led
  • Adaptive, inspectable support
  • Roadmap shaped by community votes
Meet Yar
Vote on Yar Features Yar Early Access

How people interact with the platform. Psychoverse’s research map and Yar’s daily companion share the same interpretable coordinates underneath, so the interface always shows why a signal matters, not just that it moved. For the deeper, dedicated overview of this first application area, see neuropsychiatry at Cytognosis .